Advertisement

U.S. markets open in 6 hours 37 minutes

S&P Futures
4,119.00
-5.50(-0.13%)
Dow Futures
32,713.00
-24.00(-0.07%)
Nasdaq Futures
13,001.75
-29.75(-0.23%)
Russell 2000 Futures
1,910.90
-3.70(-0.19%)
Crude Oil
89.55
-0.95(-1.05%)
Gold
1,804.50
-7.80(-0.43%)

Advertisement

Abbott Laboratories (ABT)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

107.91

-1.09

(-1.00%)

At close: 04:03PM EDT

107.99

+0.08

(+0.07%)

After hours:

07:52PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Williams %R

View all chart patterns

Performance Outlook

Previous Close	109.00
Open	108.09
Bid	0.00 x 900
Ask	0.00 x 800
Day's Range	107.55 - 108.80
52 Week Range	101.24 - 142.60
Volume	3,834,944
Avg. Volume	5,097,395

Market Cap	188.974B
Beta (5Y Monthly)	0.70
PE Ratio (TTM)	22.53
EPS (TTM)	4.79
Earnings Date	Oct 18, 2022 - Oct 24, 2022
Forward Dividend & Yield	1.88 (1.72%)
Ex-Dividend Date	Jul 14, 2022
1y Target Est	127.91

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-22% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ABT

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Abbott Laboratories
Weekly Stock ListLast week was the busiest of the quarter for earnings, with many sharp stock-price moves following above- or below-consensus results or changes in guidance. Through July 26, Refinitiv noted that 133 S&P 500 companies had reported earnings, with 76% beating expectations, above the long-term average of 66%. The blended (actual for those reporting and consensus for those still to report) growth rate is 6.2%, near the 5.6% expectation and indicating the "beats" have not been robust. But the sour mood coming into the quarter is being greeted with relief that profit shortfalls and lowered guidance are not rampant. Our analysts always look for companies that boost outlooks during earnings season. Raising guidance can be a catalyst for strong returns in the quarters ahead. Here is an initial list of BUY-rated companies in Argus coverage with raised guidance or increased outlooks during the 2Q22 EPS reporting season.
Rating
Fair Value
Economic Moat
9 days agoArgus Research